Financial Summary for the Third Quarter of the Fiscal Year Ending March 2026 [Japanese GAAP] (Consolidated)

Overview of Performance

For the cumulative consolidated period of the third quarter of the fiscal year ending March 2026, net sales were 103,742 million yen (up 14.4% YoY), operating income was 24,571 million yen (up 36.4% YoY), ordinary income was 24,219 million yen (up 36.5% YoY), and net income attributable to owners of parent for the quarter was 17,447 million yen (up 34.6% YoY). Comprehensive income also rose significantly to 20,317 million yen (up 45.0% YoY). By segment, the Electronics Business posted net sales of 71,169 million yen, and the Medical and Pharmaceutical Business recorded 28,061 million yen, with profits increasing in both businesses. The equity ratio increased to 55.5%, demonstrating a strengthened financial base.

Dividend and Share-Related Information

On December 1, 2025, a 2-for-1 stock split was implemented for ordinary shares. The dividend forecast for the fiscal year ending March 2026 is 72.50 yen per share at year-end (after considering the stock split), with no revision to the dividend forecast. Without considering the stock split, the annual dividend amount would be 310.00 yen. The number of shares outstanding stood at 116,839,616 shares, and the number of treasury shares was 5,562,854 shares, a decrease compared to the same period last year. The earnings guidance has been revised, projecting full-year net sales of 133,000 million yen (up 11.8% YoY), operating income of 29,600 million yen (up 34.1% YoY), and net income attributable to owners of parent of 20,100 million yen (up 86.5% YoY).